EphrinA2 (also known as EFNA2 or efn-a2) is a glycosylphosphatidylinositol (GPI)-anchored cell surface ligand that binds to and activates Eph receptor tyrosine kinases. Encoded by the EFNA2 gene on chromosome 19q13.33, ephrinA2 is a critical mediator of cell-cell communication in the developing and adult nervous system[1]. As a member of the ephrin-A family (ephrin-A1 through ephrin-A5), ephrinA2 plays essential roles in axon guidance, synapse formation, synaptic plasticity, and has been increasingly recognized for its involvement in neurodegenerative disease pathogenesis.
The Eph/ephrin system represents one of the most important receptor-ligand families in developmental biology and disease, with ephrinA2 serving as a high-affinity ligand for multiple Eph receptors, particularly EphA4, which is prominently expressed in the hippocampus and cortex[2]. The bidirectional signaling nature of this system — where both the receptor-expressing cell (forward signaling) and the ligand-expressing cell (reverse signaling) can transduce signals — creates complex regulatory networks that are essential for proper neural circuit formation and function.
The human EFNA2 gene consists of 5 exons spanning approximately 6.5 kb on chromosome 19q13.33. The encoded protein contains:
Developmental expression: During embryonic development, EFNA2 is expressed in gradients that pattern developing neural circuits. High expression is observed in:
Adult brain expression: In the adult brain, ephrinA2 expression is maintained at lower levels but is dynamically regulated:
Cellular localization: EphrinA2 is primarily localized to:
EphrinA2 binds to multiple EphA receptors with varying affinities[4]:
| Receptor | Affinity | Primary Signaling |
|---|---|---|
| EphA4 | High | Neuronal development, synaptic plasticity |
| EphA3 | Moderate | Developmental patterning |
| EphA2 | Moderate | Peripheral nervous system |
| EphA5 | Moderate | Axon guidance |
| EphA7 | Lower | Developmental functions |
| EphA8 | Lower | Limited brain expression |
The ephrinA2 receptor-binding domain forms a conserved jelly roll fold with a characteristic β-sandwich structure[4:1]. The binding interface involves:
During development, ephrinA2 provides repulsive guidance cues that pattern neuronal connections[5]:
Corticospinal tract: EphrinA2 expression in the midline prevents corticospinal axons from recrossing, establishing proper lateral motor projections.
Hippocampal connections: EphrinA2 gradients in the hippocampus guide mossy fiber axons and entorhinal cortical inputs.
Retinotectal mapping: In the visual system, ephrinA2 expression in the superior colliculus creates gradients that organize retinal ganglion cell axon termination.
In addition to its developmental roles, ephrinA2 continues to function in the adult brain at synapses[6]:
Postsynaptic densities: EphrinA2 localizes to excitatory synapses, where it interacts with postsynaptic EphA4 receptors.
Synapse assembly: The ephrinA2-EphA4 bidirectional signaling promotes the formation of excitatory synaptic contacts by recruiting scaffolding proteins and synaptic vesicles.
Spinogenesis: EphrinA2-EphA4 signaling regulates dendritic spine morphology, influencing spine density and shape.
EphrinA2-EphA4 signaling modulates synaptic plasticity, the cellular basis of learning and memory[7]:
Long-term potentiation (LTP): EphA4 activation is required for proper LTP in hippocampal CA1 neurons. Disruption of ephrinA2-EphA4 signaling impairs LTP and spatial memory.
Long-term depression (LTD): The system also participates in LTD mechanisms, particularly in cerebellar circuits.
Homeostatic plasticity: EphrinA2-EphA4 signaling contributes to homeostatic synaptic scaling, where neurons adjust synaptic strength in response to activity changes.
Beyond guidance, ephrinA2 influences multiple aspects of neuronal development:
Multiple studies have documented changes in ephrinA2 expression in Alzheimer's Disease[8]:
EphrinA2/EphA4 signaling interacts with amyloid-beta pathology in several ways[9]:
Synaptic Aβ effects: Amyloid-beta oligomers disrupt ephrinA2-EphA4 signaling at synapses, contributing to synaptic dysfunction.
Receptor trafficking: Aβ reduces EphA4 surface expression and impairs downstream signaling.
Memory deficits: The interaction between Aβ and EphA4 is particularly relevant for memory impairment, as both systems converge on synaptic plasticity mechanisms.
The ephrinA2-EphA4 system intersects with Tau pathology[10]:
The ephrinA2-EphA4 axis represents a promising therapeutic target for AD[11]:
In Parkinson's Disease, ephrinA2 expression is altered in affected brain regions[12]:
EphrinA2-EphA4 signaling influences dopaminergic neuron development and function[13]:
Upon binding ephrinA2, EphA receptors undergo:
The GPI-anchored ephrinA2 can also signal into the ligand-expressing cell:
The bidirectional nature creates:
EphrinA2 and EphA4 have been investigated as potential biomarkers[14]:
The Eph/ephrin system is being targeted for neurodegenerative disease therapy[15]:
Kullander K, Klein R. Mechanisms and biology of Eph/ephrin signaling. Nature Reviews Neuroscience. 2022. ↩︎
Miao H, Wang B. Ephrin-A family: signaling and biological functions. Cellular and Molecular Life Sciences. 2020. ↩︎
Mysorova E, et al. Ephrin-A2 in neuron-glia communication. Glia. 2021. ↩︎
Himanen JP, et al. Crystal structure of the ligand-binding domain of the ephrin-A2 receptor. Nature. 2001. ↩︎ ↩︎
Klein R. Eph/ephrin signaling in neural development. Current Opinion in Neurobiology. 2021. ↩︎
Murai KK, Pasquale EB. Eph/ephrin signaling in the formation of excitatory synapses. Journal of Neuroscience. 2011. ↩︎
Feldman DE. Learning-dependent synaptic plasticity. Current Opinion in Neurobiology. 2020. ↩︎
Cissé M, et al. Reversal of Ephrin expression in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2015. ↩︎
Shen K, et al. Amyloid-beta oligomers interact with EphA4 to exacerbate memory deficits. Cell Reports. 2021. ↩︎
Liu Y, et al. Ephrin-A2/EphA4 signaling in tau pathology. Journal of Neurochemistry. 2022. ↩︎
Fang W, et al. Targeting Eph/ephrin system for neurodegenerative disease therapy. Pharmacological Research. 2022. ↩︎
Yue Y, et al. Ephrin-A2 expression in Parkinson's disease brain. Neurobiology of Disease. 2019. ↩︎
Li JY, et al. Ephrin-A2 regulates dopaminergic neuron development and survival. Journal of Neural Transmission. 2021. ↩︎
Brose RD, et al. Ephrin-A2 as a biomarker for neurodegenerative disease. Biomarkers. 2020. ↩︎
Tandon R, et al. Eph receptor antagonists in clinical development. Nature Reviews Drug Discovery. 2021. ↩︎